Clinical Trials Logo
  1. Home
  2. Recurrent Cancer
  3. NCT04784221

Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse — NANOPRO  

Recurrent Cancer Clinical Trial

Official title:
Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse: NANOPRO, a Non-randomized Phase II Study

Clinical Trial Summary

This is a prospective multicenter non-randomized phase II study: proton therapy with nanoparticles based on polysiloxane and gadolinium chelates injectable intravenously

Clinical Trial Description

This is a prospective multicenter non-randomized phase II study: proton therapy with nanoparticles based on polysiloxane and gadolinium chelates injectable intravenously in recurrent tumors ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04784221
Study type Interventional
Source Centre Francois Baclesse
Contact Delphine LEROUGE, MD
Phone 332455050
Email d.lerouge@baclesse.unicancer.fr
Status Not yet recruiting
Phase Phase 2
Start date June 2024
Completion date September 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05045040 - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions N/A
Recruiting NCT05415475 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors Phase 1
Completed NCT04596865 - Recurrence After Whipple's (RAW) Study
Recruiting NCT06103617 - Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer Phase 2
Completed NCT05364905 - Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
Recruiting NCT05396300 - A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors Phase 1
Completed NCT03441100 - TCR-engineered T Cells in Solid Tumors: IMA202-101 Phase 1
Recruiting NCT05359445 - IMA401 TCER® in Recurrent and/or Refractory Solid Tumors Phase 1
Recruiting NCT03686124 - ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors Phase 1
Not yet recruiting NCT04889742 - Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors Phase 2
Recruiting NCT05189054 - Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
Completed NCT03132038 - Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck Phase 2
Not yet recruiting NCT06208657 - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Phase 1/Phase 2
Not yet recruiting NCT02410187 - SBRT for Extra-cranial Oligorecurrent Tumor Phase 2
Recruiting NCT05855811 - PREventing Second Cancers With DOSTARlimab Phase 2
Recruiting NCT05626829 - Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma Phase 2
Completed NCT03941262 - Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Phase 1
Not yet recruiting NCT06372574 - A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors Phase 1
Completed NCT05200195 - Deep Learning Model for the Prediction of Post-LT HCC Recurrence
Completed NCT03760952 - Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling